Sponsor Dossier
Recordati Rare Diseases
Sponsor Dossier for Recordati Rare Diseases. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: Carbaglu
- Brand: COSMEGEN
- Brand: CYSTADANE
- Brand: CYSTADROPS
- Brand: ISTURISA
- Brand: PEDEA
- Brand: QARZIBA
- Brand: SIGNIFOR
- Device (sponsor): Subcutaneous/intramuscular injection set, medicated
About
Recordati Rare Diseases is an Australian Private Company with ABN 26627263094, registered in NSW and currently active.
Portfolio
Recordati Rare Diseases has 9 brands on the ARTG, all of which are indexable and have Product Information on file. Three brands have at least one PBS-listed item, six brands have PBAC outcome records, and four brands have AusPARs on record. Notable brands include Carbaglu, COSMEGEN, CYSTADANE, CYSTADROPS, ISTURISA, PEDEA, QARZIBA, SIGNIFOR, and SYLVANT.
Therapeutic focus —
Rare Disease: 3 brands — Endocrinology: 3 brands — Oncology: 2 brands — Ophthalmology: 1 brand
PBS footprint
Three brands in the Recordati Rare Diseases portfolio are PBS-listed, with the latest PBS schedule date being 2026-05-01.
Regulatory activity
The most recent PBAC outcome for Recordati Rare Diseases is dated 2024-09-01, with six brands holding PBAC outcomes on record. The most recent AusPAR is dated 2022-05-06, with four brands holding AusPAR records.